In Brief: Urohealth
This article was originally published in The Gray Sheet
Executive Summary
Urohealth: Receives conditional IDE approval from FDA for clinical trials of RelaX, a valved intraurethral catheter for the management of female incontinence. The device is designed to be left within the urethra for 29 days. Urohealth claims that possible advantages of the Relax over similar devices such as UroMed's Reliance include decreased risk of infection, convenience and "ease of use." Unlike the Reliance, the Relax can be used during sexual intercourse, the company adds. Relax is priced "competitively" at approximately $110 a month or $1200-1500 a year. The conditional IDE approval allows the company "to begin filing for investigational review board (IRB) approvals at designated clinical sites around the country and to begin clinical trials as the IRBs approvals are granted." The company plans on conducting clinical trials with approximately 130 patients at up to 12 sites...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.